ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer von Miller, R.E., Leary, A., Scott, C.L., Serra, V., Lord, C.J., Bowtell, D., Chang, D.K., Garsed, D.W., Jonkers, J., Ledermann, J.A., Nik-Zainal, S., Ray-Coquard, I., Shah, S.P., Matias-Guiu, X., Swisher, E.M., Yates, L.R.

Volltext

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer von Sandhu, S.K., Omlin, A., Hylands, L., Miranda, S., Barber, L.J., Riisnaes, R., Reid, A.H., Attard, G., Chen, L., Kozarewa, I., Gevensleben, H., Campbell, J., Fenwick, K., Assiotis, I., Olmos, D., Yap, T.A., Fong, P., Tunariu, N., Koh, D., Molife, L.R., Kaye, S., Lord, C.J., Ashworth, A., de Bono, J.

Volltext

137 Haploid Genetic Screens to Identify Determinants of Drug Toxicity and Resistance von Pettitt, S.J, Rehman, F, Brough, R, Lord, C.J, Ashworth, A

Volltext

318 Novel therapeutic targets for ARID1A mutant ovarian clear cell carcinoma (OCCC) von Miller, R.E, Bajrami, I, Brough, R, Konde, A, Campbell, J, Rafiq, R, Ashworth, A, Lord, C.J

Volltext

147 An integrated approach for identifying E-cadherin synthetic lethality networks von Bajrami, I, Pettitt, S.J, Brough, R, Pemberton, H, Kastrev, D, Fontebasso, Y, Frankum, J, Campbell, J, Ashworth, A, Lord, C.J

Volltext

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer von Tutt, A N J, Lord, C J, McCabe, N, Farmer, H, Turner, N, Martin, N M, Jackson, S P, Smith, G C M, Ashworth, A

Volltext

106 Identifying KRAS New Synthetic Lethality Relationships in Cancer von Carvalho, S, Aarts, M, Riffell, J, Torrance, C, Lord, C.J, Ashworth, A

Volltext

88 Genome-wide drug sensitivity screens in haploid mouse embryonic stem cells von Pettitt, S.J, Krastev, D, Pemberton, H, Fontebasso, Y, Bajrami, I, Kozarewa, I, Frankum, J, Rafiq, R, Campbell, J, Brough, R, Ashworth, A, Lord, C.J

Volltext

122 INVITED Tumour – Stroma Interactions in Breast Cancer Metastasis von Isacke, C.M, Murugaesu, N, Iravani, M, Johnson, D.A, Ashworth, A, Lord, C.J

Volltext

288 Synthetic Lethality in ERCC1-deficient Non-Small Cell Lung Cancer von Postel-Vinay, S, Bajrami, I, Friboulet, L, Jaco, I, Fontebasso, Y, Olaussen, K.A, Soria, J.C, André, F, Lord, C.J, Ashworth, A

Volltext

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer von Van Baelen, K, Geukens, T, Maetens, M, Tjan-Heijnen, V, Lord, C J, Linn, S, Bidard, F-C, Richard, F, Yang, W W, Steele, R E, Pettitt, S J, Van Ongeval, C, De Schepper, M, Isnaldi, E, Nevelsteen, I, Smeets, A, Punie, K, Voorwerk, L, Wildiers, H, Floris, G, Vincent-Salomon, A, Derksen, P W B, Neven, P, Senkus, E, Sawyer, E, Kok, M, Desmedt, C

Volltext

298 (PB286): Targeting GPR89 as a novel therapeutic strategy for breast cancer von Ferro, R., Carroll, A., Hickman, O., Vlachogiannis, G., Trendell, J., Krastev, D., Pettitt, S., Amodeo, V., Annunziato, S., Jonkers, J., Liv, N., Pardo, M., Roumeliotis, T.I., Choudhary, J., Natrajan, R., Grigoriadis, A., Madhusudhan, M.S., Haider, S., Lord, C.J., Tutt, A.

Volltext

405P HRD biomarkers in blood samples from BRCA1/BRCA2-associated advanced breast cancer (BC) patients (pts) von Serra, V., Domenech, H., Pettitt, S.J., Proszek, P., Pedretti, F., Ropero, A. Herencia, Hernandez, A. Rodriguez, Suñol, A., Viaplana, C., Vivo, J. Domenech, Gutierrez-Enriquez, S., Oliveira, M., Mateo, J., Prat, A., Lord, C.J., Tutt, A.N.J., Llop-Guevara, A., Balmaña, J.

Volltext

Profiles of strontium and barium in Mercenaria mercenaria and Spisula solidissima shells von Stecher, H.A., Krantz, D.E., Lord, C.J., Luther, G.W., Bock, K.W.

Volltext

A decade of clinical development of PARP inhibitors in perspective von Mateo, J., Lord, C.J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S.B., de Bono, J.S.

Volltext

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer von Harvey-Jones, E., Raghunandan, M., Robbez-Masson, L., Magraner-Pardo, L., Alaguthurai, T., Yablonovitch, A., Yen, J., Xiao, H., Brough, R., Frankum, J., Song, F., Yeung, J., Savy, T., Gulati, A., Alexander, J., Kemp, H., Starling, C., Konde, A., Marlow, R., Cheang, M., Proszek, P., Hubank, M., Cai, M., Trendell, J., Lu, R., Liccardo, R., Ravindran, N., Llop-Guevara, A., Rodriguez, O., Balmana, J., Lukashchuk, N., Dorschner, M., Drusbosky, L., Roxanis, I., Serra, V., Haider, S., Pettitt, S.J., Lord, C.J., Tutt, A.N.J.

Volltext

815TiP ENGOT/GYN1/NCRI: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ATARI) von Banerjee, S., Leary, A., Lheureux, S., Stewart, J., Attygalle, A., Vroobel, K., Gill, S., Ali, Z., Tai, J., Toms, C., Natrajan, R., Lord, C.J., Porta, N., Bliss, J.

Volltext

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer von Postel-Vinay, S, Bajrami, I, Friboulet, L, Elliott, R, Fontebasso, Y, Dorvault, N, Olaussen, K A, André, F, Soria, J-C, Lord, C J, Ashworth, A

Volltext

The anion channel GPR89 is a novel oncogene associated with tumour specific dependency in breast cancer von Ferro, R., Carroll, A., Mendes-Pereira, A., Reen, V., Roxanis, I., Annunziato, S., Jonkers, J., Liv, N., Alexander, J., Quist, J., Pardo, M., Roumeliotis, T.I., Choudhary, J.S., Weekes, D., Marra, P., Natrajan, R., Grigoriadis, A., Haider, S., Lord, C.J., Tutt, A.J.

Volltext

SP-0258: Potentiation of anti-tumor immune effects by PARP Inhibitors von Chabanon, R., Muirhead, G., Krastev, D., Adam, J., Garrido, M., Morel, D., Dorvault, N., Pettitt, S., Tutt, A.N.J., Marabelle, A., Soria, J.C., Lord, C.J., Postel-Vinay, S.

Volltext